• 제목/요약/키워드: thyroid therapy

검색결과 271건 처리시간 0.025초

전뇌 방사선 치료 시 갑상선 차폐체의 주변선량 차폐효과에 대한 유용성 평가 (Evaluation of usability of the shielding effect for thyroid shield for peripheral dose during whole brain radiation therapy)

  • 양명식;차석용;박주경;이승훈;김양수;이선영
    • 대한방사선치료학회지
    • /
    • 제26권2호
    • /
    • pp.265-272
    • /
    • 2014
  • 목 적 : 전뇌 방사선 치료 시 산란선으로 인하여 영향을 받는 갑상선의 피폭선량을 감소시키기 위해 차폐체를 사용하여 갑상선의 차폐 효과를 평가하고자 한다. 대상 및 방법 : 갑상선의 피폭선량을 측정하기 위해 선형가속기(Clinac iX. VARIAN, USA)를 이용하여 6 MV X선, 300 cGy를 인체모형팬텀에 대향 2문 조사하였다. 갑상선의 입사표면선량을 측정하기 위해 인체모형팬텀의 10번째 슬라이스 표면에 유리선량계 다섯 개를 1.5 cm 간격으로 위치시킨 후 차폐체 미사용, bismuth 차폐체 사용, 0.5 mmPb 차폐체 사용, 자체 제작한 1.0 mmPb 차폐체를 사용하여 각각 5회씩 측정하여 평균값을 산출하였다. 또한, 같은 위치에서 갑상선 심부선량을 측정하기 위해서 인체모형팬텀의 10번째 슬라이스 2.5 cm 깊이에서 유리선량계 다섯 개를 1.5 cm 간격으로 위치시킨 후 차폐체 미사용, bismuth 차폐체 사용, 0.5 mmPb 차폐체 사용, 자체 제작한 1.0 mmPb 차폐체를 사용하여 각각 5회씩 측정하여 평균값을 산출하였다. 결 과 : 갑상선의 입사표면선량은 차폐체 미사용 시 44.89 mGy로 측정되었고, bismuth 차폐체는 36.03 mGy, 0.5 mmPb 차폐체는 31.03 mGy, 자체 제작한 1.0 mmPb 차폐체는 23.21 mGy로 측정되었다. 또한, 갑상선의 심부선량은 차폐체 미사용 시 36.10 mGy로 측정되었고, bismuth 차폐체는 34.52 mGy, 0.5 mmPb 차폐체는 32.28 mGy, 자체 제작한 1.0 mmPb 차폐체는 25.50 mGy로 측정되었다. 결 론 : 전뇌 방사선 치료 시 방사선 조사면 밖의 영역에서 발생하는 이차 산란 및 누출 선량에 의해 영향을 받는 갑상선에 대하여 차폐체를 사용했을 때 갑상선 심부는 약 11~30%, 갑상선 표면은 약 20~48% 정도의 피폭선량 감소 효과가 나타났다. 따라서 전뇌 방사선 치료 시 갑상선 차폐체를 사용함으로써 갑상선을 효과적으로 보호하며 치료를 시행할 수 있을 것으로 사료된다.

뇌 전이 분화 갑상선암 (Brain Metastases from Well-Differentiated Thyroid Carcinoma)

  • 이잔디;윤종호;장항석;박정수
    • 대한두경부종양학회지
    • /
    • 제20권1호
    • /
    • pp.7-12
    • /
    • 2004
  • Background and Objectives: Brain metastasis from well-differentiated thyroid carcinoma is uncommon, and the treatment remains controversial. In this study, we analyzed cases of brain metastasis from well differentiated thyroid carcinoma to determine optimal treatment. Material and Methods: From March 1986 to May 2003, we experienced 13 cases of brain metastases from well-differentiated thyroid carcinomas. There were 6 men and 7 women with a mean age of 62.3 years. The time interval detecting the brain metastasis, treatment methods, outcomes, and the prognostic factors were analyzed. Results: In 11 patients, brain metastasis was found at a mean of 96 months after thyroid surgery (range, 1-204months). In 1 patient, brain metastasis was found simultaneously with the thyroid cancer. In the remaining one, brain metastasis was presented as the first sign. Treatment included gamma knife therapy in 2, external radiation therapy (ExRT) in 2, resection and ExRT in 2, gamma knife therapy and ExRT in 2 and intracranial holmium injection in 1. Three patients received no treatment. The mean survival was 20.5months (1-119 months). Only 2 patients with early detection remained alive after treatment (23months and 119months). The age, sex, primary tumor size, combined organs of distant metastasis and treatment methods did not affect the prognosis. There were noticeable symptomatic improvements in patients who received any kind of treatment for brain metastasis. Conclusion: Early detection and treatment of brain metastasis appears to bring symptomatic relief and improve survival. Therefore, early screening for brain metastasis is recommended for patients with symptoms. However, further study is needed to determine the optimal method of treatment.

Effect of therapeutic radioiodine activity on ablation response in differentiated thyroid cancer patients with cut-off serum thyroglobulin levels after 2 weeks of thyroid hormone withdrawal: a retrospective study

  • Ji Young Lee;Hee-Sung Song;Young Hwan Kim
    • Journal of Medicine and Life Science
    • /
    • 제19권3호
    • /
    • pp.95-102
    • /
    • 2022
  • This retrospective study aimed to investigate whether there was a difference in the success rate of removal of residual thyroid tissue in patients with the same cutoff serum thyroglobulin (Tg) value-measured 2 weeks after thyroid hormone withdrawal (THW)-for different radioactive iodine (RAI) activities. We identified 132 patients with papillary thyroid cancer who were treated with total thyroidectomy and RAI therapy to evaluate the efficacy of three radioactivities of I-131: 1,110, 3,700, and 5,550 MBq. Serum Tg testing was performed 1 week before RAI treatment and 2 weeks after THW (pre-Tg); the cutoff pre-Tg level was below 10 ng/mL. Stimulated Tg levels were measured on the day of I-131 administration (off-Tg). After 6 months of treatment, we compared the groups for complete ablation, defined as no uptake on a diagnostic I-131 scan, stimulated Tg level of <1.0 ng/mL, and Tg antibody level of <100 ng/mL. Ninety-five patients (72.0%) achieved complete ablation, with 57.1% (8/14), 78.2% (68/87), and 61.3% (19/31) in the 1,110 MBq, 3,700 MBq, and 5,550 MBq groups, respectively. There was no significant difference in the complete ablation rates between the three groups. In the multivariate analysis, the off-Tg level was a significant predictor of complete ablation. RAI therapy with low radioactivity (1,110 MBq) seemed sufficient for ablation in patients with papillary thyroid cancer with a pre-Tg level below 10 ng/mL. The off-Tg level is a promising and useful predictor of complete ablation after initial RAI therapy.

갑상선과 후두에 발생한 다발성 원발암 1례 (A Case of Metachronous Multiple Primary Tumor Involving the Thyroid and the Larynx)

  • 손영익;권중근;추광철
    • 대한기관식도과학회지
    • /
    • 제3권1호
    • /
    • pp.164-168
    • /
    • 1997
  • Multiple primary tumors in the head and neck are not uncommon, however those in the thyroid and the larynx are known to be very rare. In most cases of multiple primary tumors involving the thyroid and the larynx, lesions are observed usually simultaneously and thyroid tumors are found incidentally during the laryngeal tumor surgery. In rare cases, thyroid tumors are found metachronously after radiation therapy of laryngeal cancer. The authors recently experienced a case of multiple primary tumor involving the thyroid and the larynx, in which thyroid papillary carcinoma was the index tumor and the laryngeal squamous carcinoma was the meatachronous second tumor. Both tumors showed aggressive local extension and regional nodal meatastasis with tumor collision in the same node. The patient died of recurrent or of residual squamous carcinoma shortly after main surgical treatment index thyroid cancer.

  • PDF

유두상 갑상선암 환자의 갑상선절제술 후 합병증에 대한 임상경과 보고 3례 (A Clinical Study on 3 Cases of Complications after Total Thyroidectomy and Neck Dissection in the Papillary Thyroid Carcinoma)

  • 박은영;권형근;공복철;김동철
    • 대한한방부인과학회지
    • /
    • 제26권3호
    • /
    • pp.103-113
    • /
    • 2013
  • Objectives: Thyroid cancer is the most common cancer for female in Korea. This study aims to report the effects of Korean medicine on complications after total thyroidectomy and neck dissection in the papillary thyroid carcinoma. Methods: The 3 patients with papillary thyroid carcinoma were treated by Korean medicine such as acupuncture, moxibustion and pharmacopuncture therapy. We evaluated the results of treatments by change of symptoms. Results: After treatments such as acupuncture, moxibustion and pharmacopuncture therapy except herb medicine, the symptoms of complications after total thyroidectomy and neck dissection were improved. Conclusions: This study shows that Korean medicine has effects on complications after total thyroidectomy and neck dissection in the papillary thyroid carcinoma.

갑상선암 환자에서 전종격동의 전이성 암처럼 보이는 흉선의 방사성옥소 섭취 (Thymic Radioiodine Uptake Mimicking Metastatic Papillary Carcinoma in the Anterior Mediastinum)

  • 박찬희;이명훈
    • 대한핵의학회지
    • /
    • 제36권1호
    • /
    • pp.87-89
    • /
    • 2002
  • A 30 year-old female patient with papillary thyroid carcinoma received her fifth radioiodine ablation therapy after the subtotal thyroidectomy. The scan, which was peformed one week after the last therapy, revealed residual uptake in the thyroid bed and uptake in the anterior mediastinum suggesting metastasis. However, further evaluation of the thorax with chest CT and camera-based FDG PET confirmed normal thymus without metastatic focus. Occasionally thymus remains intact in adult and has avidity for I-131 and FDG. Therefore, normal thymus (instead of metastasis) should be considered in patients with well differentiated thyroid carcinoma and anterior mediastinal radioiodine uptake.

Preliminary study on the efficacy of xerostomia treatment with sialocentesis targeting thyroid disease patients given radioiodine therapy

  • Kim, Euy-Hyun;Lee, Dong-Keon;Kim, Chang-Woo;Song, In-Seok;Jun, Sang-Ho
    • Maxillofacial Plastic and Reconstructive Surgery
    • /
    • 제41권
    • /
    • pp.39.1-39.6
    • /
    • 2019
  • Background: Radioiodine therapy has been widely used for thyroid disease patients, but hyposalivation and xerostomia may occur in 10~30% of patients. Sialocentesis is a procedure that removes inflammatory substances in the salivary duct and expands the duct for the secretion and delivery of saliva. In this study, thyroid disease patients treated with radioactive iodine were selected among the patients with xerostomia who visited the hospital, and the effect of sialocentesis was compared and analyzed. And then, comparison between the radioiodine therapy-experienced group and the non-radioiodine therapy-experienced group was conducted. Results: In this study, we studied xerostomia patients who underwent radioiodine therapy due to thyroid diseases and who underwent sialocentesis at the Korea University Anam Hospital. Sialocentesis is conducted by one surgeon. The study also compares the clinical symptoms before and after the surgery. After the procedure, the discomfort due to xerostomia was reduced, and the symptom was improved effectively. Conclusions: The results of this study showed that sialocentesis has a clinical effect in the treatment of xerostomia, which is a side effect of radioiodine therapy. In addition, the possibility of further clinical application of sialocentesis in the future is found.

Sodium Iodide Symporter (NIS)를 이용한 분자영상 (Molecular Imaging Using Sodium Iodide Symporter (NIS))

  • 조제열
    • 대한핵의학회지
    • /
    • 제38권2호
    • /
    • pp.152-160
    • /
    • 2004
  • Radioiodide uptake in thyroid follicular epithelial cells, mediated by a plasma membrane transporter, sodium iodide symporter (NIS), provides a first step mechanism for thyroid cancer detection by radioiodide injection and effective radioiodide treatment for patients with invasive, recurrent, and/or metastatic thyroid cancers after total thyroidectomy. NIS gene transfer to tumor cells may significantly and specifically enhance internal radioactive accumulation of tumors following radioiodide administration, and result in better tumor control. NIS gene transfers have been successfully performed in a variety of tumor animal models by either plasmid-mediated transfection or virus (adenovirus or retrovirus)-mediated gene delivery. These animal models include nude mice xenografted with human melanoma, glioma, breast cancer or prostate cancer, rats with subcutaneous thyroid tumor implantation, as well as the rat intracranial glioma model. In these animal models, non-invasive imaging of in vivo tumors by gamma camera scintigraphy after radioiodide or technetium injection has been performed successfully, suggesting that the NIS can serve as an imaging reporter gene for gene therapy trials. In addition, the tumor killing effects of I-131, ReO4-188 and At-211 after NIS gene transfer have been demonstrated in in vitro clonogenic assays and in vivo radioiodide therapy studies, suggesting that NIS gene can also serve as a therapeutic agent when combined with radioiodide injection. Better NIS-mediated imaging and tumor treatment by radioiodide requires a more efficient and specific system of gene delivery with better retention of radioiodide in tumor. Results thus far are, however, promising, and suggest that NIS gene transfer followed by radioiodide treatment will allow non-invasive in vivo imaging to assess the outcome of gene therapy and provide a therapeutic strategy for a variety of human diseases.

유즙분비가 있는 갑상선암 환자에서 I-131 치료 (Radioiodine Therapy in a Patient with Papillary Thyroid Carcinoma associated with Breast Uptake; Hyperprolactinemia due to Empty Sella Syndrome)

  • 배문선;박찬희;서정호;김경래
    • 대한핵의학회지
    • /
    • 제32권1호
    • /
    • pp.109-113
    • /
    • 1998
  • 진단적 I-131 스캔에서 유방의 섭취는 주로 수유 여성에서 보인다고 알려져 있으나 수유 여부와는 관련 없이 나타나는 경우도 보고되어 있다. 갑상선 암으로 갑상선 절제술 후 I-131 치료를 위해 시행한 진단적 스캔에서 유방의 섭취를 보인 환자에서 고프로락틴 혈증에 의한 유류증의 발견 및 이를 근거로한 뇌 단층 촬영상 Empty sella가 진단되어 이를 bromocriptine으로 치료한 후, 유방 섭취의 소실이 확인 되어 I-131 치료를 시행한 경우가 있어 이를 보고하고자 한다.

  • PDF